NHS Scotland has commissioned Hemlibra (emicizumab), by Chungai Pharma UK Ltd and Roche Products Ltd, to treat people with congenital haemophilia A without factor VIII inhibitors.
Hemlibra is self-administered by injection, and has multiple dosing options ranging from once a week to once every four weeks.
In clinical trials, Hemlibra dosed once or every two weeks led to a statistically significant and clinically meaningful reduction in treated bleeds compared to on-demand treatment.